Loading organizations...
Financière Spin-off Luxembourgeoise operates as a specialized venture capital fund dedicated to fostering innovation by financing newly established companies. The firm focuses on supporting the commercialization of research outcomes originating from universities and corporations, providing capital and strategic guidance for these early-stage and spin-off ventures. Its core capability lies in transforming promising research and intellectual property into viable commercial enterprises through targeted investment and hands-on accompaniment.
The entity is an integral part of the INVESTSUD Group, an established investment player with over four decades of experience supporting small and medium-sized enterprises. This broader group identified a critical need for focused investment in the challenging domain of research commercialization, leading to the creation of Financière Spin-off Luxembourgeoise as a dedicated vehicle for such opportunities. Pierre Detrixhe serves as the operational manager, guiding the fund's activities and portfolio development within this specialized niche.
Financière Spin-off Luxembourgeoise primarily serves entrepreneurs launching innovative companies that leverage scientific and technological breakthroughs. It targets nascent businesses aiming to bring academic or corporate research to market. The firm's overarching mission is to act as an amplifier of ambitions, enabling these entrepreneurial ventures to navigate their early stages, accelerate development, and contribute to the broader economic landscape by translating groundbreaking ideas into commercial success.
Financière Spin-off Luxembourgeoise has 4 tracked investments across 3 companies. The latest tracked deal is $15.4M Series B in PDC*line Pharma in January 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 22, 2020 | PDC*line Pharma | $15.4M Series B | — | Sangwoo LEE, Noshaq, Sambrinvest, Sfpi Fpim, Shinhan Cognitive Start UP Fund, UTC 2019 Bioventurefund |
| Dec 6, 2016 | PDC*line Pharma | $4.3M Debt / Other Equity | — | Baudouin Jolly, Jean Paul Prieels, Riccardo Cortese, Serge Goblet, Auvergne Rhône Alpes Initiative, Noshaq, Parness, Spinventure, Wallonia Biotech Coaching Incubator |
| Nov 21, 2013 | iSTAR Medical | $5.4M Series A | Ekaterina Smirnyagina, Philippe Degive | Namur Invest |
| Mar 28, 2012 | Promethera Biosciences | $31.4M Debt / Series B | — | Atmi, Boehringer Ingelheim, Life Sciences Research Partners, Mitsui & CO. Global Investment, Nivelinvest, Sambrinvest, Shire, Sopartec, Sriw, Vesalius Biocapital, Vives Louvain Technology Fund, Walloon Region |